| . | Total cohort . | Graft loss (death-censored) . | No graft loss . | P . |
|---|---|---|---|---|
| Total number, n | 709 | 49 (6.9%) | 660 (93.1%) | |
| Demographics | ||||
| Age, years, mean (SD) | 54.04 (±14.35) | 60.63 (±13.12) | 53.55 (±14.3) | .001 |
| Caucasian, n (%) | 701 (98.9) | 48 (98) | 653 (98.9) | .531 |
| Female, n (%) | 285 (40.2) | 17 (34.7) | 268 (40.6) | .415 |
| Transplantation data | ||||
| Time since transplantation, years, median (IQR) | 5.4 (2.23–10.13) | 6.1 (2.53–8.59) | 5.4 (2.1–10.28) | .676 |
| Living donor, n (%) | 224 (31.6) | 11 (22.4) | 213 (32.7) | .139 |
| Expanded criteria donor, n (%) | 228 (32.2) | 30 (61.2) | 198 (30) | <.001 |
| DGF, n (%) | 226 (31.9) | 23 (47.9) | 203 (32) | .024 |
| DSA positive at inclusion, n (%) | 51 (7.2) | 10 (21.3) | 41 (6.4) | <.001 |
| History of ABMR, n (%) | 25 (3.5) | 10 (21.3) | 15 (2.3) | <.001 |
| History of CMR, n (%) | 209 (29.5) | 22 (44.9) | 187 (28.3) | .015 |
| Immunosuppressive therapy, n (%) | ||||
| Cyclosporine A | 274 (38.6) | 14 (28.6) | 260 (39.4) | .133 |
| Tacrolimus | 329 (46.4) | 20 (40.8) | 309 (46.8) | .416 |
| MMF/MPA | 659 (92.9) | 44 (89.9) | 615 (93.2) | .372 |
| Azathioprine | 12 (1.7) | 3 (6.1) | 9 (1.4) | .013 |
| Everolimus or rapamycin | 65 (9.2) | 6 (12.2) | 59 (8.9) | .439 |
| Belatacept | 16 (2.3) | 4 (8.2) | 12 (1.8) | .004 |
| Steroids | 309 (43.6) | 33 (67.3) | 276 (41.8) | <.001 |
| History of underlying kidney disease, n (%) | ||||
| Polycystic kidney disease | 109 (15.4) | 10 (20.4) | 99 (15.0) | .311 |
| Glomerulonephritis | 88 (12.4) | 8 (16.3) | 80 (12.1) | .389 |
| Hypertensive nephropathy | 55 (7.8) | 4 (8.2) | 51 (7.7) | .921 |
| Diabetic nephropathy | 20 (2.8) | 6 (12.2) | 14 (2.1) | <.001 |
| Others | 437 (61.6) | 21 (42.9) | 416 (63.0) | .005 |
| Comorbidities, n (%) | ||||
| Diabetes mellitus | 160 (22.6) | 19 (38.8) | 141 (21.4) | .005 |
| Hypertension | 691 (97.5) | 49 (100) | 642 (97.3) | .242 |
| Coronary heart disease | 134 (18.9) | 16 (32.7) | 118 (17.9) | .011 |
| Peripheral arterial occlusive disease | 63 (8.9) | 6 (12.2) | 57 (8.6) | .392 |
| Heart failure | 297 (41.9) | 34 (69.4) | 263 (39.8) | <.001 |
| Cerebrovascular disease | 63 (8.9) | 5 (10.2) | 58 (8.8) | .737 |
| . | Total cohort . | Graft loss (death-censored) . | No graft loss . | P . |
|---|---|---|---|---|
| Total number, n | 709 | 49 (6.9%) | 660 (93.1%) | |
| Demographics | ||||
| Age, years, mean (SD) | 54.04 (±14.35) | 60.63 (±13.12) | 53.55 (±14.3) | .001 |
| Caucasian, n (%) | 701 (98.9) | 48 (98) | 653 (98.9) | .531 |
| Female, n (%) | 285 (40.2) | 17 (34.7) | 268 (40.6) | .415 |
| Transplantation data | ||||
| Time since transplantation, years, median (IQR) | 5.4 (2.23–10.13) | 6.1 (2.53–8.59) | 5.4 (2.1–10.28) | .676 |
| Living donor, n (%) | 224 (31.6) | 11 (22.4) | 213 (32.7) | .139 |
| Expanded criteria donor, n (%) | 228 (32.2) | 30 (61.2) | 198 (30) | <.001 |
| DGF, n (%) | 226 (31.9) | 23 (47.9) | 203 (32) | .024 |
| DSA positive at inclusion, n (%) | 51 (7.2) | 10 (21.3) | 41 (6.4) | <.001 |
| History of ABMR, n (%) | 25 (3.5) | 10 (21.3) | 15 (2.3) | <.001 |
| History of CMR, n (%) | 209 (29.5) | 22 (44.9) | 187 (28.3) | .015 |
| Immunosuppressive therapy, n (%) | ||||
| Cyclosporine A | 274 (38.6) | 14 (28.6) | 260 (39.4) | .133 |
| Tacrolimus | 329 (46.4) | 20 (40.8) | 309 (46.8) | .416 |
| MMF/MPA | 659 (92.9) | 44 (89.9) | 615 (93.2) | .372 |
| Azathioprine | 12 (1.7) | 3 (6.1) | 9 (1.4) | .013 |
| Everolimus or rapamycin | 65 (9.2) | 6 (12.2) | 59 (8.9) | .439 |
| Belatacept | 16 (2.3) | 4 (8.2) | 12 (1.8) | .004 |
| Steroids | 309 (43.6) | 33 (67.3) | 276 (41.8) | <.001 |
| History of underlying kidney disease, n (%) | ||||
| Polycystic kidney disease | 109 (15.4) | 10 (20.4) | 99 (15.0) | .311 |
| Glomerulonephritis | 88 (12.4) | 8 (16.3) | 80 (12.1) | .389 |
| Hypertensive nephropathy | 55 (7.8) | 4 (8.2) | 51 (7.7) | .921 |
| Diabetic nephropathy | 20 (2.8) | 6 (12.2) | 14 (2.1) | <.001 |
| Others | 437 (61.6) | 21 (42.9) | 416 (63.0) | .005 |
| Comorbidities, n (%) | ||||
| Diabetes mellitus | 160 (22.6) | 19 (38.8) | 141 (21.4) | .005 |
| Hypertension | 691 (97.5) | 49 (100) | 642 (97.3) | .242 |
| Coronary heart disease | 134 (18.9) | 16 (32.7) | 118 (17.9) | .011 |
| Peripheral arterial occlusive disease | 63 (8.9) | 6 (12.2) | 57 (8.6) | .392 |
| Heart failure | 297 (41.9) | 34 (69.4) | 263 (39.8) | <.001 |
| Cerebrovascular disease | 63 (8.9) | 5 (10.2) | 58 (8.8) | .737 |
P-values are indicated for comparison of the differences between patients with graft loss and without graft loss regarding baseline characteristics (Mann–Whitney U test, Student's t-test or χ2 test as appropriate). Bold values denote statistical significance at the P < 0.05 level.
Expanded criteria donors = brain-dead donors ≥60 years old or between 50 and 59 years old with at least two of the following criteria: history of arterial hypertension, last serum creatinine >1.5 mg/dL or cerebrovascular death.
DGF = need for at least one postoperative dialysis in the first 7 days post-transplantation.
Coronary heart disease = history of myocardial infarction, coronary bypass surgery and/or coronary angioplasty.
Heart failure = any degree of insufficiency.
ABMR, antibody-mediated rejection; CMR, cell-mediated rejection; MMF, mycophenolate mofetil; MPA, mycophenolic acid.
| . | Total cohort . | Graft loss (death-censored) . | No graft loss . | P . |
|---|---|---|---|---|
| Total number, n | 709 | 49 (6.9%) | 660 (93.1%) | |
| Demographics | ||||
| Age, years, mean (SD) | 54.04 (±14.35) | 60.63 (±13.12) | 53.55 (±14.3) | .001 |
| Caucasian, n (%) | 701 (98.9) | 48 (98) | 653 (98.9) | .531 |
| Female, n (%) | 285 (40.2) | 17 (34.7) | 268 (40.6) | .415 |
| Transplantation data | ||||
| Time since transplantation, years, median (IQR) | 5.4 (2.23–10.13) | 6.1 (2.53–8.59) | 5.4 (2.1–10.28) | .676 |
| Living donor, n (%) | 224 (31.6) | 11 (22.4) | 213 (32.7) | .139 |
| Expanded criteria donor, n (%) | 228 (32.2) | 30 (61.2) | 198 (30) | <.001 |
| DGF, n (%) | 226 (31.9) | 23 (47.9) | 203 (32) | .024 |
| DSA positive at inclusion, n (%) | 51 (7.2) | 10 (21.3) | 41 (6.4) | <.001 |
| History of ABMR, n (%) | 25 (3.5) | 10 (21.3) | 15 (2.3) | <.001 |
| History of CMR, n (%) | 209 (29.5) | 22 (44.9) | 187 (28.3) | .015 |
| Immunosuppressive therapy, n (%) | ||||
| Cyclosporine A | 274 (38.6) | 14 (28.6) | 260 (39.4) | .133 |
| Tacrolimus | 329 (46.4) | 20 (40.8) | 309 (46.8) | .416 |
| MMF/MPA | 659 (92.9) | 44 (89.9) | 615 (93.2) | .372 |
| Azathioprine | 12 (1.7) | 3 (6.1) | 9 (1.4) | .013 |
| Everolimus or rapamycin | 65 (9.2) | 6 (12.2) | 59 (8.9) | .439 |
| Belatacept | 16 (2.3) | 4 (8.2) | 12 (1.8) | .004 |
| Steroids | 309 (43.6) | 33 (67.3) | 276 (41.8) | <.001 |
| History of underlying kidney disease, n (%) | ||||
| Polycystic kidney disease | 109 (15.4) | 10 (20.4) | 99 (15.0) | .311 |
| Glomerulonephritis | 88 (12.4) | 8 (16.3) | 80 (12.1) | .389 |
| Hypertensive nephropathy | 55 (7.8) | 4 (8.2) | 51 (7.7) | .921 |
| Diabetic nephropathy | 20 (2.8) | 6 (12.2) | 14 (2.1) | <.001 |
| Others | 437 (61.6) | 21 (42.9) | 416 (63.0) | .005 |
| Comorbidities, n (%) | ||||
| Diabetes mellitus | 160 (22.6) | 19 (38.8) | 141 (21.4) | .005 |
| Hypertension | 691 (97.5) | 49 (100) | 642 (97.3) | .242 |
| Coronary heart disease | 134 (18.9) | 16 (32.7) | 118 (17.9) | .011 |
| Peripheral arterial occlusive disease | 63 (8.9) | 6 (12.2) | 57 (8.6) | .392 |
| Heart failure | 297 (41.9) | 34 (69.4) | 263 (39.8) | <.001 |
| Cerebrovascular disease | 63 (8.9) | 5 (10.2) | 58 (8.8) | .737 |
| . | Total cohort . | Graft loss (death-censored) . | No graft loss . | P . |
|---|---|---|---|---|
| Total number, n | 709 | 49 (6.9%) | 660 (93.1%) | |
| Demographics | ||||
| Age, years, mean (SD) | 54.04 (±14.35) | 60.63 (±13.12) | 53.55 (±14.3) | .001 |
| Caucasian, n (%) | 701 (98.9) | 48 (98) | 653 (98.9) | .531 |
| Female, n (%) | 285 (40.2) | 17 (34.7) | 268 (40.6) | .415 |
| Transplantation data | ||||
| Time since transplantation, years, median (IQR) | 5.4 (2.23–10.13) | 6.1 (2.53–8.59) | 5.4 (2.1–10.28) | .676 |
| Living donor, n (%) | 224 (31.6) | 11 (22.4) | 213 (32.7) | .139 |
| Expanded criteria donor, n (%) | 228 (32.2) | 30 (61.2) | 198 (30) | <.001 |
| DGF, n (%) | 226 (31.9) | 23 (47.9) | 203 (32) | .024 |
| DSA positive at inclusion, n (%) | 51 (7.2) | 10 (21.3) | 41 (6.4) | <.001 |
| History of ABMR, n (%) | 25 (3.5) | 10 (21.3) | 15 (2.3) | <.001 |
| History of CMR, n (%) | 209 (29.5) | 22 (44.9) | 187 (28.3) | .015 |
| Immunosuppressive therapy, n (%) | ||||
| Cyclosporine A | 274 (38.6) | 14 (28.6) | 260 (39.4) | .133 |
| Tacrolimus | 329 (46.4) | 20 (40.8) | 309 (46.8) | .416 |
| MMF/MPA | 659 (92.9) | 44 (89.9) | 615 (93.2) | .372 |
| Azathioprine | 12 (1.7) | 3 (6.1) | 9 (1.4) | .013 |
| Everolimus or rapamycin | 65 (9.2) | 6 (12.2) | 59 (8.9) | .439 |
| Belatacept | 16 (2.3) | 4 (8.2) | 12 (1.8) | .004 |
| Steroids | 309 (43.6) | 33 (67.3) | 276 (41.8) | <.001 |
| History of underlying kidney disease, n (%) | ||||
| Polycystic kidney disease | 109 (15.4) | 10 (20.4) | 99 (15.0) | .311 |
| Glomerulonephritis | 88 (12.4) | 8 (16.3) | 80 (12.1) | .389 |
| Hypertensive nephropathy | 55 (7.8) | 4 (8.2) | 51 (7.7) | .921 |
| Diabetic nephropathy | 20 (2.8) | 6 (12.2) | 14 (2.1) | <.001 |
| Others | 437 (61.6) | 21 (42.9) | 416 (63.0) | .005 |
| Comorbidities, n (%) | ||||
| Diabetes mellitus | 160 (22.6) | 19 (38.8) | 141 (21.4) | .005 |
| Hypertension | 691 (97.5) | 49 (100) | 642 (97.3) | .242 |
| Coronary heart disease | 134 (18.9) | 16 (32.7) | 118 (17.9) | .011 |
| Peripheral arterial occlusive disease | 63 (8.9) | 6 (12.2) | 57 (8.6) | .392 |
| Heart failure | 297 (41.9) | 34 (69.4) | 263 (39.8) | <.001 |
| Cerebrovascular disease | 63 (8.9) | 5 (10.2) | 58 (8.8) | .737 |
P-values are indicated for comparison of the differences between patients with graft loss and without graft loss regarding baseline characteristics (Mann–Whitney U test, Student's t-test or χ2 test as appropriate). Bold values denote statistical significance at the P < 0.05 level.
Expanded criteria donors = brain-dead donors ≥60 years old or between 50 and 59 years old with at least two of the following criteria: history of arterial hypertension, last serum creatinine >1.5 mg/dL or cerebrovascular death.
DGF = need for at least one postoperative dialysis in the first 7 days post-transplantation.
Coronary heart disease = history of myocardial infarction, coronary bypass surgery and/or coronary angioplasty.
Heart failure = any degree of insufficiency.
ABMR, antibody-mediated rejection; CMR, cell-mediated rejection; MMF, mycophenolate mofetil; MPA, mycophenolic acid.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
